Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
By D. Nathan, John B. Buse, M. Davidson, E. Ferrannini, Rury R. Holman, R. Sherwin, B. Zinman. Diabetes Care, 2009
2,670 citations recorded by the source corpus.
The consensus algorithm for the medical management of type 2 diabetes was published in August 2006 with the expectation that it would be updated, based on the availability of new interventions and new evidence to establish their clinical role. The authors continue to endorse the principles used to develop the algorithm and its major features. We are sensitive to the risks of changing the algorithm cavalierly or too frequently, without compelling new information. An update to the consensus algorithm published in January 2008 specifically addressed safety issues surrounding the thiazolidinediones. In this revision, we focus on the new classes of medications that now have more clinical data and experience.
Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/1cf454a7ca554873302c894d16550f4a80a5f19a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Molecular Biology
Citations in the corpus
- Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders (2017, background): “However, the drugs available currently are not effective in correcting the underlying cause of insulin resistance, and most patients need pharmacotherapy for the rest of their lives (Nathan et al., 2009; Qaseem et al., 2012).”
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2009, background): “Woo’s response to our study (1) and his comparison (2) of the Canadian Diabetes Association (CDA) clinical practice guidelines and the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) consensus algorithm and welcome the opportunity to address the differences ”
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). (2009, background): “hyperglycaernia.[1] Subsequently, treatment should be intensified promptly if glycosylated haemoglobin (HbA1c) values exceed the ADA target of less than 7%.”